Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Formalizes World-Class Scientific Advisory Board

GlobeNewswire July 5, 2018

Hemostemix Announces Major Milestone Achieved With First 3 U.S. Trial Sites for Phase II Clinical Trial Open for Patient Enrollment

GlobeNewswire May 30, 2018

Hemostemix Announces New EU Patent Grant

GlobeNewswire May 23, 2018

Hemostemix Announces First Patient Treated in Phase II Clinical Trial

GlobeNewswire May 3, 2018

Hemostemix Announces US FDA Clinical Trial Approval

GlobeNewswire April 19, 2018

Hemostemix Signs License Agreement with Aspire Health Science

GlobeNewswire February 26, 2018

Hemostemix Signs License Agreement with Aspire Health Science

GlobeNewswire February 23, 2018

Hemostemix Signs Manufacturing Agreement with Aspire Health Science

GlobeNewswire February 22, 2018

Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials

GlobeNewswire December 20, 2017

Hemostemix Drives Forward with Talented New Management into New Headquarters

GlobeNewswire November 30, 2017

Hemostemix Announces Agreement with CRO Service Provider Topstone Research

GlobeNewswire September 26, 2017

Acquisition and Disposition of Securities of Hemostemix Inc.

Marketwired September 19, 2017

Hemostemix Completes Conversion of Subscription Receipts and Secured Credit Financing

GlobeNewswire September 15, 2017

Hemostemix Completes Private Placement and Rights Offering

GlobeNewswire August 25, 2017

Hemostemix Inc. Announces Agreement to Resolve all Outstanding Matters with Hemostemix (Asia) Corporation (HEMA)

GlobeNewswire August 17, 2017

Hemostemix Announces Updates on Private Placement

MarketWire Canada August 15, 2017

Hemostemix Announces Updates on Rights Offering

MarketWire Canada August 15, 2017

Hemostemix Announces Updates on Rights Offering and Private Placement

MarketWire Canada July 21, 2017

Hemostemix Announces Engagement of PI Financial Corp., Rights Offering and Updates on Proposed Private Placement and Senior Secured Credit Financing

MarketWire Canada July 11, 2017

Hemostemix Announces Voting Results of the Annual and Special Meeting of Shareholders

Marketwired June 30, 2017